Marshall Wace LLP Sells 995,323 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Marshall Wace LLP decreased its stake in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 47.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,122,302 shares of the medical device company's stock after selling 995,323 shares during the quarter. Marshall Wace LLP owned 0.56% of Cooper Companies worth $103,173,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Norges Bank bought a new position in Cooper Companies during the fourth quarter worth about $217,906,000. FMR LLC raised its stake in shares of Cooper Companies by 97.6% in the 4th quarter. FMR LLC now owns 2,218,112 shares of the medical device company's stock valued at $203,911,000 after purchasing an additional 1,095,805 shares during the period. Raymond James Financial Inc. acquired a new stake in Cooper Companies in the 4th quarter valued at approximately $64,826,000. Victory Capital Management Inc. lifted its position in shares of Cooper Companies by 14.6% in the fourth quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company's stock worth $415,985,000 after purchasing an additional 574,899 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company's stock worth $543,979,000 after buying an additional 573,908 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on COO shares. Stifel Nicolaus decreased their target price on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research report on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $115.00 price objective (down from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. Citigroup decreased their target price on Cooper Companies from $115.00 to $110.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Finally, BNP Paribas raised shares of Cooper Companies to a "hold" rating in a report on Thursday, March 13th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $110.25.

Cooper Companies Stock Performance

Shares of COO traded up $0.21 on Tuesday, reaching $78.91. 376,405 shares of the company's stock traded hands, compared to its average volume of 1,409,293. The stock's 50 day simple moving average is $82.79 and its two-hundred day simple moving average is $93.29. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 52-week low of $69.81 and a 52-week high of $112.38. The stock has a market cap of $15.78 billion, a PE ratio of 40.48, a PEG ratio of 2.25 and a beta of 1.01.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. On average, analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.